English Name: Peramivir

CAS No.: 229614-55-5

Molecular formula: C15H28N4O4

Molecular weight: 328.41

EINECS No.: 1308068-626-2

Usage: pramivir was first developed by biocryst in the United States. After the introduction of yanye pharmaceutical in Japan, it was first approved to be listed on January, 2010. The drug can be used in patients with severe, Tamiflu resistant and unable to take orally. On April 5, 2013, the State Food and Drug Administration approved the new anti influenza drug pramivir sodium chloride injection. According to the website of the State Food and drug administration, pramivir is a new anti influenza virus drug. The existing clinical trial data show that it is effective for influenza A and B. H7n9 belongs to influenza A virus subtype. Pramivir sodium chloride injection is the first neuraminidase inhibitor administered intravenously in China. It provides a new treatment option for patients with severe influenza, patients who cannot accept inhaled or oral neuraminidase inhibitors, and patients with poor efficacy or drug resistance to other neuraminidase inhibitors.